How Doctors Decide Between — Chemo, Immunotherapy and Targeted Therapy

You can ask — and your oncologist should explain their reasoning clearly. But eligibility for targeted therapy and immunotherapy is decided by your tumour biology, not by preference or cost. If a treatment requires a biomarker your tumour does not carry, it is unlikely to work and carries real side-effect risk. A productive conversation focuses on what your test results showed and what the recommended option is expected to achieve, rather than asking for a specific drug by name.

Biomarker testing looks for specific gene mutations, protein levels or other molecular features in your tumour tissue — usually from the biopsy you have already had. For many cancers, these results directly determine whether targeted therapy or immunotherapy is on the table. Your oncologist will tell you which markers apply to your cancer type. Results typically take one to two weeks. Without them, a targeted or immune treatment recommendation cannot be made safely.

Not universally — and comparing them as if one is always superior misses the point. Targeted therapy works very well for patients whose tumours carry the matching molecular target, and has limited effect for those who do not. Chemotherapy works more broadly but also affects healthy cells. Neither is better in the abstract. Your oncologist is choosing the option most likely to work for your specific tumour, and that is the only comparison that matters for your situation.

No. Immunotherapy is used at various stages for certain cancers — sometimes as a treatment alongside surgery, sometimes as first-line therapy for advanced disease. Whether it is appropriate at your stage depends on your cancer type and your biomarker results. For some cancers, NCCN and ESMO guidance includes immunotherapy as a first-line option from the point of diagnosis. Ask your oncologist whether your stage and markers place you in a group where it is indicated.

This is a real and common concern, and your oncologist should know about it. Some targeted therapies have generic versions available in India at substantially lower cost. Patient access programmes exist for certain medicines. For some cancers, chemotherapy alone or in combination is an equally recommended alternative. Never quietly forgo a recommended treatment without telling your team — there may be options they can work through with you once they know cost is a factor.

Combinations of two are standard in many treatment protocols — chemotherapy with immunotherapy, for example, or chemotherapy with a targeted agent. All three together at the same time is unusual outside a clinical trial. Your oncologist designs the combination based on what is proven for your cancer type and what your body can safely handle. Each treatment added to a regimen also adds potential side effects, so combinations are chosen deliberately, not by stacking more in hope of more benefit.

It depends on how much testing is needed. If a biopsy has already been done and standard pathology is back, a plan may be outlined at your first oncology appointment. If biomarker testing is needed — and for many cancers it is — results take one to two weeks after the sample reaches the laboratory. Waiting for those results is not delay; it is what makes the recommendation accurate. If you are worried about the time, ask your team what is being awaited and when to expect it.

Yes, and a confident oncologist will not object to one. A second opinion is especially worth seeking when the diagnosis is rare, when biomarker results are borderline, or when you feel the explanation was unclear. Bring all your reports, biopsy slides and scan images — most centres can review them without repeating tests. A second opinion confirms the plan or refines it; either outcome is in your interest. CION teams regularly provide second opinions for patients seen elsewhere.